CALT: Calliditas Earnings growth forecast for next year

calliditas.se - graphic logo of issuer CALT

The development of unique treatments for rare kidney pathologies ensures stable demand and long-term returns for Calliditas Therapeutics (CALT). The high intellectual potential of Swedish scientists guarantees innovative progress. However, integration with Asahi Kasei and pricing controls in the US are weighing on margins. EPS growth prospects for next year reflect current market expectations, where 2490.80 represents the current level of the metric.

CALT - Calliditas Therapeutics, Inc. Expected net earnings per share growth next year over the range 07/04/2022 - 09/28/2024

Analytical breakdowns and data insights for company Calliditas (CALT)

- price and consensus price forecast:
Price Chart Calliditas Therapeutics AB|CALT - Broker Consensus Forecast
- market capitalization information:
Market Capitalization Calliditas Therapeutics|CALT - Total Enterprise Value
- book capitalization indicators:
Accounting Value per Share Calliditas Therapeutics|CALT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio calliditas.se|CALT - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Calliditas Therapeutics|CALT - Long-Term Debt to Capital|Short-Term Debt to Equity Calliditas Therapeutics|CALT - Company Debts|Debt to Book Capitalization Ratio Calliditas Therapeutics, Inc.|CALT - Company Long-Term Debt|Company Short-Term Debts Calliditas Therapeutics|Quick Ratio calliditas.se
- earnings and market ratios statistics:
CALT - Company Profit|Projected Future Earnings Calliditas Therapeutics|CALT - Business Payback Period|Projected Price to Earnings Calliditas Therapeutics, Inc.|CALT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Calliditas Therapeutics AB|CALT - Operating profit EBITDA|Earnings per share for the last twelve months Calliditas Therapeutics|CALT - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months calliditas.se|CALT - Earnings per share increase in current year|Expected earnings per share growth for next year Calliditas Therapeutics
- total revenue and sales volume data:
CALT - Company Total Sales|Projected Sales Volume calliditas.se|CALT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Calliditas Therapeutics
Summary company analysis:CALT, Calliditas Therapeutics AB
Finished products of Calliditas Therapeutics, Inc.

This indicator measures the expected earnings per share (EPS) dynamics for the next period, allowing investors to assess the potential for business expansion and the risk of capital stagnation. By analyzing current expectations for the EPS n+1 growth rate, one can confirm the resilience of Calliditas Therapeutics (CALT), whose innovative medical developments create a demand cycle independent of macroeconomic factors, providing the asset with defensive qualities.

Key competitors

Net earnings per share growth forecast for next year Travere Therapeutics, Inc.|Projected earnings per share growth rate for next year ARDX (Ardelyx, Inc.)|Earnings growth forecast for next year PROK|AKBA - Expected net earnings per share growth next year|caratherapeutics.com - Expected earnings per share growth for next year|DiaMedica Pharma (DMAC) - Expected net earnings per share growth next year|UNCY: Expected earnings per share growth for next year|Expected earnings per share trend next year RMTI (rockwellmed.com)|CVKD: Earnings growth forecast for next year|Projected earnings per share growth rate for next year CDT|Net earnings per share growth forecast for next year Renalytix Plc|Net earnings per share growth forecast for next year ZVSA